The 2026 market still files the healthcare lawyer as a compliance hire.

A CHC credential is not a substitute for a bar card. The American Health Law Association, a 501(c)(3) educational body, reports more than 12,000 members and states that members include health lawyers, compliance and privacy officers, finance officers, consultants, physicians, nurses and public-health officials. Comprehensive membership, at $545 a year, is designed for the health lawyer, with all 17 Practice Groups. Basic membership, at $325 a year, is tailored for compliance officers, security officers, paralegals and specialized professionals. That product split is the market’s own confession that the two seats are not the same hire.

The Health Care Compliance Association describes Certified in Healthcare Compliance as demonstrating knowledge to help healthcare organizations manage risk, meet regulatory obligations and promote integrity through compliance programs. The exam is largely based on compliance work experience. Initial exam fees are $350 for members and $450 for non-members. Eligibility as published ties to professional work experience and continuing-education units, not to a JD or bar admission. A healthcare attorney seat that requires a JD and an active bar is a different product. The compliance-officer salary page on this site owns the CHC paycheck; that sibling is where that band lives.

The Association of Corporate Counsel 2025 specialty ranking of median total cash lists securities, antitrust, bankruptcy/creditor, pension/ERISA and government relations as the top five. Healthcare appears after corporate governance and before banking and finance. Compliance and Regulatory sit further down the same list. Senior management-level roles show less specialty variation, the executive summary says. Healthcare industry mean hours in that survey were 46.5 — an hours figure, not a wage, and not a license to move the healthcare attorney onto the compliance-officer mean.

Federal healthcare-lawyer seats sit in the HHS Office of the General Counsel, not in a hospital compliance office. The Federal Register notice of 14 March 2025 restates the Office of the General Counsel as the sole designated source of legal advice to HHS operating divisions except the Office of Inspector General, which has its own Office of Counsel. A GS-15 Attorney Advisor posting in the CMS Division, series GS-0905-15, requires a JD from an ABA-accredited law school, at least four years of professional legal experience after bar admission, an active bar, and United States citizenship. Groups named as hiring include Program Integrity, Program Enforcement, Program Review and Litigation — fraud and waste, Medicare reimbursement, drug-price negotiation, APA challenges. The Rest-of-United-States range on that posting is $146,481 to $190,424 before locality; New York-Newark cash is the 2026-NY table in the previous section, not that Rest-of-United-States range.

HHS-OIG’s Office of Counsel, with more than 120 attorneys and staff, provides all legal services for the Inspector General in six branches, including Administrative and Civil Remedies and Industry Guidance. The Office of Inspector General has about 1,650 employees, including about 500 law-enforcement officers. State Medicaid Fraud Control Units operate in 53 jurisdictions — each of the 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands — usually inside the state attorney general’s office, and must employ at least an investigator, an auditor and an attorney. Those are lawyer seats. They are not Certified in Healthcare Compliance hires.

Maximum Fair Prices for ten Part D drugs took effect on 1 January 2026. The Centers for Medicare & Medicaid Services fact sheet of 15 August 2024 stated those ten drugs accounted for $56.2 billion in Part D gross covered costs in 2023, about 20 percent of Part D gross, and estimated $6 billion of illustrative net savings if 2026 prices had applied in 2023, with $1.5 billion projected enrollee savings in 2026. On 25 November 2025 CMS announced fifteen additional drugs, Maximum Fair Prices effective 1 January 2027, covering 5.3 million Part D users in 2024 and about $42.5 billion of gross covered costs. Life-sciences general counsel, pricing and reimbursement counsel, Part D formulary counsel, and HHS Office of the General Counsel Program Review — the GS-15 CMS Division posting expressly lists drug-price negotiation — are in a live file, not a prospective one.

Public Law 119-21, identified by the American Medical Association as signed on 4 July 2025, rewrites Medicaid eligibility and provider-tax finance on a 2026–2032 clock and includes a temporary one-year 2.5 percent conversion-factor update for 2026. AAMC restated CMS implementing guidance of 21 November 2025: beginning 1 October 2026, states may not impose new or increased provider taxes not enacted or imposed as of 4 July 2025; existing taxes in expansion states phase the indirect hold-harmless threshold down to 3.5 percent in 2032. The CMS Office of the Actuary already places those limits inside the 2026 national-health-expenditure path, with 2026 Medicaid growth at 4.8 percent and direct-purchase insurance enrollment expected to decline by 3.7 million as enhanced marketplace subsidies expire. Health-system general counsel and state-hospital-association outside counsel on Medicaid finance are 2026 advice seats. They are not first-year compliance-program seats.

The Calendar Year 2026 Physician Fee Schedule final rule, fact sheet dated 31 October 2025, sets two conversion factors: qualifying alternative-payment-model $33.57 and non-qualifying $33.40, with a minus 2.5 percent efficiency adjustment on non-time-based services. The 2026 Medicare Advantage Rate Announcement of 7 April 2025 projected a 5.06 percent increase, or over $25 billion, in Medicare Advantage payments to plans in calendar 2026, completed phase-in of the 2024 CMS-HCC model, and continued the Inflation Reduction Act Part D redesign with a 2026 catastrophic out-of-pocket threshold of $2,100. A Northern District of Texas decision on 25 September 2025, as restated by WilmerHale on 2 October 2025, vacated the 2023 RADV Final Rule on Administrative Procedure Act notice-and-comment grounds. Medicare Advantage regulatory litigators and CMS Division litigators are the seats that sentence hires. Audit-support staff are not.

Oregon SB 951, enacted 9 June 2025 as restated by Wilson Sonsini on 13 June 2025, restricts MSO ownership and control of professional corporations, with new-entity rules effective 1 January 2026 and existing-entity rules 1 January 2029. California SB 351, approved 6 October 2025 as Chapter 409, prohibits a private equity group or hedge fund involved with a California physician or dental practice from interfering with professional judgment and from controlling specified clinical, hiring, payer-contract and billing functions. Those statutes hire healthcare regulatory and private-equity transactional counsel. They do not hire a Certified in Healthcare Compliance officer to amend the management agreement.

Two 2025 vacaturs also tell a general counsel what not to staff for. ACLA v. FDA, Eastern District of Texas, final judgment 31 March 2025, vacated the 6 May 2024 laboratory-developed-test rule in its entirety; remaining laboratory work sits under CLIA, which is a CMS seat, not an FDA 510(k) build. SEC v. Jarkesy, 603 U.S. 109 (27 June 2024), entitles a defendant to a jury when the government seeks civil penalties for a common-law-like fraud; the HHS Departmental Appeals Board in Holy Cross Hospital, DAB CR6830 (2026), declined to treat Jarkesy or Loper Bright as invalidating a hospital price-transparency civil money penalty. The government is already staffing the defense of those challenges. The company-side product is a senior attorney and partner APA file, not a sub-regulatory FAQ desk.